BDRL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BDRL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Blonder Tongue Laboratories's average Accounts Payable for the three months ended in Jun. 2024 was $2.33 Mil. Blonder Tongue Laboratories's Cost of Goods Sold for the three months ended in Jun. 2024 was $1.84 Mil. Hence, Blonder Tongue Laboratories's Days Payable for the three months ended in Jun. 2024 was 115.63.
The historical rank and industry rank for Blonder Tongue Laboratories's Days Payable or its related term are showing as below:
During the past 13 years, Blonder Tongue Laboratories's highest Days Payable was 99.42. The lowest was 26.59. And the median was 50.36.
Blonder Tongue Laboratories's Days Payable increased from Jun. 2023 (86.57) to Jun. 2024 (115.63). It may suggest that Blonder Tongue Laboratories delayed paying its suppliers.
The historical data trend for Blonder Tongue Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blonder Tongue Laboratories Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Payable | Get a 7-Day Free Trial |
![]() |
![]() |
64.90 | 86.42 | 78.89 | 67.72 | 87.30 |
Blonder Tongue Laboratories Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Days Payable | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
86.57 | 91.49 | 76.17 | 125.10 | 115.63 |
For the Communication Equipment subindustry, Blonder Tongue Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Hardware industry and Technology sector, Blonder Tongue Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Blonder Tongue Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Blonder Tongue Laboratories's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as
Days Payable (A: Dec. 2023 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2022 ) | + | Accounts Payable (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (2.431 | + | 1.986) | / | 2 ) | / | 9.234 | * | 365 |
= | 2.2085 | / | 9.234 | * | 365 | ||||
= | 87.30 |
Blonder Tongue Laboratories's Days Payable for the quarter that ended in Jun. 2024 is calculated as:
Days Payable (Q: Jun. 2024 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Mar. 2024 ) | + | Accounts Payable (Q: Jun. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Jun. 2024 ) | * | Days in Period |
= | ( (2.338 | + | 2.32) | / | 2 ) | / | 1.838 | * | 365 / 4 |
= | 2.329 | / | 1.838 | * | 365 / 4 | ||||
= | 115.63 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Blonder Tongue Laboratories's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Williams James H /nj/ | director | C/O BLONDER TONGUE LABORATORIES INC, ONE JAKE BROWN RD, OLD BRIDGE NJ 08857 |
Palle Robert J Jr | director, 10 percent owner, officer: President and COO | C/O BLONDER TONGUE LABORATORIES INC, ONE JAKE BROWN ROAD, OLD BRIDGE NJ 08857 |
Eric S Skolnik | officer: Senior Vice President - CFO | C/O BLONDER TONGUE LABORATORIES INC, ONE JAKE BROWN ROAD, OLD BRIDGE NJ 08857 |
John E Burke | director | 1540 BARDSEY LANE, LOWER GWYNEDD PA 19002 |
Anthony J Bruno | director | C/O BLONDER TONGUE LABORATORIES, INC., ONE JAKE BROWN ROAD, OLD BRIDGE NJ 08857 |
Cavalry Fund I Lp | 10 percent owner | 82 EAST ALLENDALE ROAD, SUITE 5B, SADDLE RIVER NJ 07458 |
Michael Hawkey | director | 2160 GOLD STREET, SAN JOSE CA 95002 |
Rick E Briggs | director | C/O BLONDER TONGUE LABORATORIES, INC., ONE JAKE BROWN ROAD, OLD BRIDGE NJ 08857 |
Edward Rowland Grauch | officer: CEO & President | 3208 HIGHWAY 98, MEXICO BEACH FL 32456 |
Jeffrey W Smith | officer: Vice President - Sales | C/O BLONDER TONGUE LABORATORIES, INC., ONE JAKE BROWN ROAD, OLD BRIDGE NJ 08857 |
Ronald Vincent Alterio | officer: VP-Engineering, CTO | C/O BLONDER TONGUE LABORATORIES, ONE JAKE BROWN ROAD, OLD BRIDGE NJ 08857 |
Gary P Scharmett | director | |
Steven L Shea | director | C/O BLONDER TONGUE LABORATORIES, INC., ONE JAKE BROWN ROAD, OLD BRIDGE NJ 08857 |
Stephen K Necessary | director | |
Bruce A Gureck | officer: Exec VP/COO | 4671 BOCAIRE BLVD, BOCA RATON FL 33487 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 02-24-2023
By ACCESSWIRE ACCESSWIRE • 08-15-2022
By ACCESSWIRE • 11-06-2023
By ACCESSWIRE ACCESSWIRE • 08-05-2022
By ACCESSWIRE ACCESSWIRE • 11-04-2022
By GuruFocus Research • 02-12-2024
By GuruFocus Research • 02-12-2024
By ACCESSWIRE ACCESSWIRE • 06-08-2022
By GuruFocus Research • 02-12-2024
By GuruFocus Research • 02-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.